Paul Hopper is the Founder of Chimeric Therapeutics. He has over 25 years experience in the biotech, healthcare & life sciences sectors. Focussed on start-up and rapid growth companies, he has served as either Founder, Chairman, non-executive director, or CEO of more than fourteen companies in the US, Australia and Asia. Previous and current Boards include Viralytics, Imugene, Prescient Therapeutics, Polynoma and Suda Medical. His experience covers extensive fund raising in US, Australia, Asia and Europe, and he has deep experience in corporate governance, risk and strategy. He also has many years experience in providing corporate advice and guidance, financial analysis and management of companies of differing sizes and financial circumstances.
Chief Operating Officer
Until recently Ms Chow was Head of Global Marketing, Analytics and Commercial Operations at leading global CAR T company Kite Pharmaceuticals (acquired by Gilead Sciences in 2017 for US$11.9bn). Ms Chow was responsible for assessing and prioritizing research and external assets for development, ensuring optimal clinical development of the Kite pipeline for global commercialisation. Ms Chow has more than 20 years of commercial strategy and marketing experience focused in cellular therapy, hematology and oncology. Formerly Ms Chow was the Global Cell Therapy Commercial Lead at Celgene Corporation (NASDAQ:CELG) and was responsible for designing and developing the global CAR T commercial strategy and operating model. Ms Chow was also formerly at Roche (SWX:RO), Nycomed/Takeda (TYO:4502) and Schering Canada.
Dr Syed Rizvi
Chief Medical Officer
Until recently Dr Rizvi was one of the founding executive team at NASDAQ listed global CAR T company Legend Biotech, where he was head of the CAR T program serving as VP Clinical Development and Medical Affairs. Dr Rizvi is a CAR T specialist with more than 20 years of oncology drug development experience, including taking drugs through regulatory approvals and commercial launches. Formerly he was head of the CAR T and immuno-oncology program at Celgene Corporation (NASDAQ:CELG) serving as Global Medical Affairs and head of Hematology for US Medical Affairs. Dr Rizvi previously also held global clinical leadership roles in oncology programs at Novartis (SWX:NOVN) and Merck (NYSE:MRK).
Dr Eliot Bourk
Vice President, Business and Corporate Development
Dr Bourk joins Chimeric from Kite Pharmaceuticals where he led early commercial strategy, responsible for the optimisation of a portfolio of early-stage cell therapy pipeline assets and for guiding business development strategies and transactions. Within this role, Dr Bourk guided product development decisions to maximise future commercial opportunity, led the development of corporate disease strategies for solid tumors and hematological malignancies and partnered with translational research teams to focus research and development efforts. Additionally at Kite, Dr Bourk was instrumental in defining the business development priorities for solid tumors and hematological malignancies, building academic and industry partnerships to identify opportunities and leading commercial diligence for all transactions. Prior to joining Kite, Dr Bourk was a founding member of the cell therapy commercial team at Celgene Corporation. During his time at Celgene, Dr Bourk was the commercial lead for the development of next generation CAR T platforms, working in partnership with research, development and technical operations to provide commercial insight to guide development and investment in next generation technologies. At Celgene, Dr Bourk also was instrumental in the development of the Celgene global CAR T commercial strategy including the development and implementation of the cell therapy commercial model.
Chief Financial Officer & Joint Company Secretary
The Company currently outsources its finance and company secretarial requirements to a specialist public practice, ‘The CFO Solution’. Mr Phillip Hains (CA, MBA) brings over 30 years of experience in corporate secretarial, accounting and general management through his firm The CFO Solution, a boutique professional services firm for listed companies.
Mr Hains is currently the Company Secretary of several ASX listed companies including Imugene Ltd (ASX:IMU), Immuron Ltd (ASX:IMC), SelfWealth Limited (ASX:SWF), Total Brain Limited (ASX:TTB) and SUDA Pharmaceuticals Ltd (ASX:SUD).
Over 20 years experience as a biotech analyst and life science investor across ASX listed and private companies through her investment management roles at Asia Union Investments and life science fund BioScience Managers. Experienced in portfolio management of assets from private start-ups through to FDA approvals. Ms Gartner is currently a Director of the National Foundation of Medical Research and Innovation.